Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients—A Systematic Review and Meta-Analysis

Aromatase inhibitors (AIs) have been considered first-line therapy for patients with hormone-dependent breast cancer due to their high efficacy and good tolerability. However, AIs are not free of adverse events, and studies show that therapy with AIs is associated with an increased risk of cardiovas...

Descripción completa

Detalles Bibliográficos
Autores principales: Boszkiewicz, Kamila, Piwowar, Agnieszka, Petryszyn, Paweł
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181297/
https://www.ncbi.nlm.nih.gov/pubmed/35683517
http://dx.doi.org/10.3390/jcm11113133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181297/
https://www.ncbi.nlm.nih.gov/pubmed/35683517
http://dx.doi.org/10.3390/jcm11113133

Ejemplares similares